Peter Pang

Peter Pang

Asia Pacific Counsel, Corporate
Peter Pang represents corporates, investment banks and private equity funds in the U.S. and Hong Kong on capital markets transactions, cross-border mergers and acquisitions, private equity transactions and other general corporate matters.

経歴

Highlights from Mr. Pang’s experience include representing:

Capital Markets

  •  Li Auto Inc. in its:
    • US$2 billion SEC-registered at-the-market (ATM) American depositary share (ADS) offering;
    • HK$11.8 billion (US$1.52 billion) SEC-registered global offering and dual-primary listing on the Hong Kong Stock Exchange with a weighted voting rights structure;
    • US$862.5 million Rule 144A/Regulation S offering of 0.25% convertible senior notes due 2028;
    • US$1.57 billion SEC-registered follow-on ADS offering; and
    • US$1.64 billion U.S. IPO (Nasdaq) and concurrent private placements;
  • Zhihu Inc. in its:
    • HK$833.6 million (US$106.3 million) SEC-registered global offering and dual-primary listing on the Hong Kong Stock Exchange with a weighted voting rights structure; and
    • US$775 million U.S. IPO (NYSE) and concurrent private placements;
  • Trip.com Group Limited (formerly Ctrip.com International, Ltd.) in its:
    • HK$9.75 billion (US$1.25 billion) SEC-registered global offering and secondary listing on the Hong Kong Stock Exchange;
    • US$500 million Regulation S offering of 1.50% Exchangeable Senior Notes due 2027;
    • US$213 million convertible notes and share investments in MakeMyTrip Limited;
    • US$2.6 billion concurrent SEC-registered follow-on ADS offering and Rule 144A/Regulation S offering of 1.25% Convertible Senior Notes due 2022 and ordinary shares; and
    • US$1 billion convertible notes investments by Booking and Hillhouse Capital;
  • the underwriters in Linklogis Inc.’s HK$9.16 billion (US$1.18 billion) Hong Kong IPO with a weighted voting rights structure;
  • Meituan in its US$2 billion Rule 144A/Regulation S offering of 2.125% Senior Notes due 2025 and 3.05% Senior Notes due 2030 listed on the Hong Kong Stock Exchange;
  • China Renaissance Holdings Limited in its HK$2.7 billion (US$350 million) Hong Kong IPO;
  • NIO Inc. in its:
    • US$235 million private placement of convertible notes; and
    • US$1.15 billion U.S. IPO (NYSE);
  • Baidu, Inc. in its SEC-registered, SGX-listed investment-grade debt offerings:
    • US$300 million 1.625% Notes due 2027 and US$700 million 2.375% Notes due 2031;
    • US$650 million 1.720% Notes due 2026 and US$300 million 2.375% Notes due 2030;
    • US$600 million 3.075% Notes due 2025 and US$400 million 3.425% Notes due 2030;
    • US$250 million reopening of 4.375% Notes due 2024; and
    • US$600 million 4.375% Notes due 2024 and US$400 million 4.875% Notes due 2028;
  • Weibo Corporation in its SEC-registered offering of SGX-listed US$800 million 3.500% Notes due 2024;
  • VCREDIT Holdings Limited in its HK$1.45 billion (US$184.5 million) Hong Kong IPO;
  • Yixin Group Limited in its HK$6.77 billion (US$870 million) Hong Kong IPO;
  • the underwriters in Four Seasons Education (Cayman) Inc.’s the US$108 million U.S. IPO (NYSE);
  • JOYY Inc. (formerly YY Inc.) in its US$463 million SEC-registered follow-on ADS offering;
  • BitAuto Holdings Limited in its US$150 million Regulation S offering of convertible notes; and
  • various U.S. public companies in their ongoing U.S. securities law compliance and corporate governance matters, such as periodic reporting under the Securities Exchange Act of 1934, beneficial ownership reports, employee stock ownership plans, annual and extraordinary shareholder meetings, SEC correspondence, depositary receipts and Depository Trust Company matters, among other representations.

M&A and Private Equity

  • Capital Group Private Markets in its investment with GL Capital for a 29% stake in JINXIN Medical Investment Group Limited;
  • The Carlyle Group in its US$64 million investment for a 15.7% stake in Zhongmei Healthcare Group Limited;
  • ECARX Holdings Inc. in its merger with COVA Acquisition Corp. at an enterprise value of US$3.8 billion, resulting in ECARX being a U.S.-listed company;
  • Mitsui Engineering & Shipbuilding Co., Ltd. in its €164 million acquisition of a 99.36% stake in TGE Marine AG;
  • National Silicon Industry Group in its €170 million takeover of Okmetic Oyj through a voluntary public tender offer;
  • Nikkei Inc. in its £844 million acquisition of FT Group from Pearson PLC;
  • NIO Inc. in its Series D preferred share financing;
  • Peet’s Coffee & Tea, Inc., an affiliate of Joh. A. Benckiser, in its Greater China joint venture with Hillhouse Capital and various follow-up commercial arrangements;
  • SunEdison, Inc. and TerraForm Global in their acquisition of and investment in various state-owned and private renewable energy assets in China;
  •  Tencent Holdings Limited in its:
    • US$42 million investment in Series D-2 preferred share financing of Yuanfudao; and
    • US$69 million acquisition, as part of an investor group including Huayi Brothers and other investors, of a 51% interest in China Jiuhao Health Industry Corporation Limited;
  • Trip.com Group Limited in:
    • the merger of eLong and Tongcheng Network, two of its investee companies;
    • its £1.4 billion acquisition of U.K.-based Skyscanner Holdings Limited through cross-border tender offer; and
    • various investments in travel and mobility-related businesses in China;
  • Visa, Inc. regarding its China strategy in the bank card clearing sector;
  • Western Digital Corporation in its:
    • divestiture of certain HDD operations and property in China; and
    • data storage and cloud solutions joint venture with Unisplendour Corporation Limited; and
  • a PRC air travel information technology service provider in its bid to acquire Navitaire.

資格等

取得学位等

  • LL.M., Duke Law School, 2006
  • LL.M., New York University School of Law, 2005
  • J.D., Fordham University School of Law, 2010
  • LL.B., Shanghai International Studies University, 2004

資格

  • New York

Peter Pang

Asia Pacific Counsel, Corporate
peter.pang@skadden.com